Skip to main content
. 2020 Apr 27;103(1):132–141. doi: 10.4269/ajtmh.19-0738

Figure 2.

Figure 2.

Flow diagram of study participants. AE = adverse event; ATP = according-to-protocol; DPIV+AS03B = adjuvant system 03B-adjuvanted inactivated tetravalent dengue virus vaccine; M = month; N = number of participants in each group; 0–1 M = participants receiving two doses of DPIV+AS03B administered 1 M apart, at M0 and M1; 0–3 M = participants receiving two doses of DPIV+AS03B administered 3 M apart, at M3 and M6; 0–1–6 M = participants receiving three doses of DPIV+AS03B with the first two given 1 M apart and the third given 6 M after the first, at M0, M1, and M6. *Non-compliance by participant and outside of window for visit (participation discontinued).